Sign in

CIK 0000921299

  • Non-accelerated filer
  • Smaller reporting company

KYNTRA BIO, INC.

Sign in to watch
Ticker
KYNB
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Entity type
Operating
EIN
770357827
Phone
+1 415-978-1200
Business address
350 BAY STREET, SUITE 100 #6009, SAN FRANCISCO, CA, 94133
Former names
FIBROGEN INC
  1. 4 Shares withheld for taxes SVP, Finance and CFO gave up 3,014 shares (to pay taxes)
  2. 4 Shares withheld for taxes SVP, China Operations gave up 3,039 shares (to pay taxes)
  3. 4 Grant or award Incoming Chief Medical Officer acquired 35,000 shares (grant or award)
  4. 3 Insider Initial Statement of Ownership
  5. 4 Exercise or conversion SVP, Clinical Dev, Drug Safety acquired 7,082 shares (option exercise)
  6. 4 Open-market sale Chief Medical Officer sold 3,351 shares at $44.01 ($147,478)
  7. 4 Open-market sale SVP, Finance and CFO sold 3,070 shares at $43.63 ($133,944)
  8. 4 Shares withheld for taxes Chief Medical Officer gave up 3,291 shares (to pay taxes)
  9. 4 Shares withheld for taxes SVP, Clinical Dev, Drug Safety gave up 2,728 shares (to pay taxes)
  10. 4 Shares withheld for taxes SVP, Finance and CFO gave up 3,014 shares (to pay taxes)
  11. 4 Shares withheld for taxes SVP, China Operations gave up 3,038 shares (to pay taxes)
  12. 4 Open-market sale Chief Medical Officer sold 10,000 shares at $50.89 ($508,900)
  13. 4 Open-market sale SVP, Finance and CFO sold 15,004 shares at $50.91 ($763,854)
  14. 4 Exercise or conversion Director acquired 6,000 shares (option exercise)
  15. 4 Open-market sale SVP, Finance and CFO sold 22,554 shares at $48.00 ($1,082,592)
  16. 4 Grant or award Director acquired 3,914 shares (grant or award)
  17. 4 Grant or award Director acquired 3,914 shares (grant or award)
  18. 3 Insider Initial Statement of Ownership
  19. 3 Insider Initial Statement of Ownership
  20. 4 Open-market sale Chief Medical Officer sold 3,351 shares at $42.35 ($141,915)

Page 12 of 38 · 760 filings